Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ACHN
- CUSIP: 00448Q20
- Web: www.achillion.com
Capitalization:- Market Cap: $638.68 million
- Outstanding Shares: 136,761,000
Average Prices:- 50 Day Moving Avg: $4.45
- 200 Day Moving Avg: $4.16
- 52 Week Range: $3.15 - $9.49
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.65
- P/E Growth: -0.44
Sales & Book Value:- Annual Revenue: $15 million
- Price / Sales: 42.58
- Book Value: $2.65 per share
- Price / Book: 1.76
Profitability:- EBIDTA: ($70,510,000.00)
- Return on Equity: -17.56%
- Return on Assets: -16.97%
Debt:- Current Ratio: 25.33%
- Quick Ratio: 25.33%
Misc:- Average Volume: 1.92 million shs.
- Beta: 1.95
- Short Ratio: 9.2
Frequently Asked Questions for Achillion Pharmaceuticals (NASDAQ:ACHN)
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
How were Achillion Pharmaceuticals' earnings last quarter?
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.16). During the same period last year, the firm posted ($0.14) EPS. View Achillion Pharmaceuticals' Earnings History.
When will Achillion Pharmaceuticals make its next earnings announcement?
Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?
8 equities research analysts have issued 12-month price objectives for Achillion Pharmaceuticals' stock. Their forecasts range from $4.00 to $16.00. On average, they expect Achillion Pharmaceuticals' share price to reach $8.71 in the next twelve months. View Analyst Ratings for Achillion Pharmaceuticals.
Who are some of Achillion Pharmaceuticals' key competitors?
Some companies that are related to Achillion Pharmaceuticals include Clinigen Group PLC (CLIN), Acorda Therapeutics (ACOR), NeuroDerm (NDRM), Omeros Corporation (OMER), Dermira (DERM), Xencor (XNCR), Retrophin (RTRX), Ascendis Pharma A/S (ASND), Dynavax Technologies Corporation (DVAX), Sangamo Therapeutics (SGMO), Amarin Corporation PLC (AMRN), Epizyme (EPZM), Aduro Biotech (ADRO), Five Prime Therapeutics (FPRX), Keryx Biopharmaceuticals (KERX), Achaogen (AKAO), Insmed (INSM) and PTC Therapeutics (PTCT).
Who are Achillion Pharmaceuticals' key executives?
Achillion Pharmaceuticals' management team includes the folowing people:
- David I. Scheer, Chairman of the Board
- Milind S. Deshpande Ph.D., President, Chief Executive Officer, Director
- Mary Kay Fenton CPA, Chief Financial Officer, Executive Vice President
- Martha E. Manning Esq., Executive Vice President, General Counsel, Corporate Secretary
- David Apelian M.D. Ph.D., Executive Vice President, Chief Medical Officer
- Joseph Truitt, Executive Vice President, Chief Commercial Officer
- Amy Jennings, Senior Vice President - Regulatory Affairs
- Michael D. Kishbauch, Director
- Frank Verwiel M.D., Director
- Jason S. Fisherman M.D., Independent Director
Who owns Achillion Pharmaceuticals stock?
Achillion Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (9.97%), Vanguard Group Inc. (7.00%), Janus Henderson Group PLC (3.31%), State Street Corp (2.91%), Numeric Investors LLC (2.15%) and Dimensional Fund Advisors LP (1.37%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish, Mary Kay Fenton and Nicole Vitullo. View Institutional Ownership Trends for Achillion Pharmaceuticals.
Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?
Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, State Street Corp, Emory University, Numeric Investors LLC, PDT Partners LLC, Northern Trust Corp, Pacad Investment Ltd. and AXA. View Insider Buying and Selling for Achillion Pharmaceuticals.
Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?
Achillion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Dimensional Fund Advisors LP, Senzar Asset Management LLC, EcoR1 Capital LLC, JPMorgan Chase & Co., FMR LLC, Los Angeles Capital Management & Equity Research Inc. and GSA Capital Partners LLP. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.
How do I buy Achillion Pharmaceuticals stock?
Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Achillion Pharmaceuticals' stock price today?
One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $4.67.
MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.63) |
| Consensus Price Target: | $8.71 (86.60% upside) |
Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/10/2017 | Robert W. Baird | Downgrade | Outperform -> Neutral | $5.00 | High |  |
| 8/9/2017 | Maxim Group | Set Price Target | Buy | $5.00 -> $7.00 | High | |
| 8/9/2017 | Chardan Capital | Lower Price Target | Neutral | $5.00 -> $4.00 | High | |
| 5/18/2017 | Leerink Swann | Upgrade | Market Perform -> Outperform | $4.00 -> $6.00 | High | |
| 4/26/2017 | Jefferies Group LLC | Reiterated Rating | Hold | | Low | |
| 2/2/2017 | Ladenburg Thalmann Financial Services | Initiated Coverage | Buy | $10.00 | N/A | |
| 11/3/2016 | Wedbush | Reiterated Rating | Outperform | $13.00 | N/A | |
| 9/15/2016 | FBR & Co | Initiated Coverage | Outperform | $16.00 | N/A | |
| 7/7/2016 | JMP Securities | Upgrade | Market Perform -> Outperform | $13.00 | N/A | |
| 12/8/2015 | William Blair | Reiterated Rating | Outperform | $16.00 | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)Earnings History by Quarter for Achillion Pharmaceuticals (NASDAQ ACHN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.17) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.16) | ($0.16) | | | View | Listen | |
| 5/4/2017 | Q1 2017 | ($0.16) | ($0.15) | | | View | N/A | |
| 2/23/2017 | Q4 2016 | ($0.18) | ($0.03) | | $15.00 million | View | N/A | |
| 11/3/2016 | Q3 | ($0.16) | ($0.15) | | | View | N/A | |
| 8/4/2016 | Q2 | ($0.15) | ($0.14) | | | View | N/A | |
| 5/3/2016 | Q116 | ($0.14) | ($0.13) | | | View | N/A | |
| 2/25/2016 | Q4 | $0.09 | $0.12 | $31.40 million | $31.60 million | View | N/A | |
| 11/5/2015 | Q3 | $0.09 | $0.19 | $32.62 million | $33.82 million | View | N/A | |
| 8/10/2015 | Q2 | ($0.18) | ($0.25) | | $0.71 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.22) | ($0.17) | | | View | N/A | |
| 3/5/2015 | Q414 | ($0.19) | ($0.21) | | | View | N/A | |
| 11/4/2014 | Q314 | ($0.18) | ($0.16) | | | View | N/A | |
| 8/7/2014 | Q214 | ($0.18) | ($0.16) | | | View | N/A | |
| 5/7/2014 | Q114 | ($0.17) | ($0.17) | | | View | N/A | |
| 3/7/2014 | Q413 | ($0.16) | ($0.14) | $0.01 million | | View | N/A | |
| 11/12/2013 | Q3 | ($0.20) | ($0.14) | | | View | N/A | |
| 5/7/2013 | Q113 | ($0.15) | ($0.14) | | | View | N/A | |
| 11/8/2012 | Q312 | ($0.17) | ($0.20) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)2017 EPS Consensus Estimate: ($0.71)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.17) | ($0.16) | ($0.17) |
| Q2 2017 | 3 | ($0.17) | ($0.17) | ($0.17) |
| Q3 2017 | 3 | ($0.18) | ($0.18) | ($0.18) |
| Q4 2017 | 1 | ($0.19) | ($0.19) | ($0.19) |
(Data provided by Zacks Investment Research)
Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Achillion Pharmaceuticals (NASDAQ:ACHN)Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 70.70%
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/22/2016 | Jason S Fisherman | Director | Buy | 10,000 | $3.96 | $39,600.00 | |
| 12/5/2016 | Mary Kay Fenton | CFO | Buy | 2,500 | $4.11 | $10,275.00 | |
| 12/2/2016 | Joel C Barrish | Insider | Buy | 2,500 | $4.06 | $10,150.00 | |
| 12/30/2015 | David Apelian | insider | Sell | 10,000 | $10.50 | $105,000.00 | |
| 12/28/2015 | Mary Kay Fenton | CFO | Sell | 43,500 | $10.08 | $438,480.00 | |
| 11/11/2015 | Nicole Vitullo | Director | Sell | 550,000 | $10.17 | $5,593,500.00 | |
| 9/25/2015 | Nicole Vitullo | Director | Sell | 9,310 | $8.22 | $76,528.20 | |
| 1/23/2015 | Mary Kay Fenton | CFO | Sell | 13,125 | $16.00 | $210,000.00 | |
| 1/21/2015 | Milind Deshpande | CEO | Sell | 100,000 | $15.00 | $1,500,000.00 | |
| 9/30/2014 | Ra Capital Management, Llc | Insider | Sell | 1,332,014 | $10.20 | $13,586,542.80 | |
| 9/29/2014 | Ra Capital Management, Llc | Insider | Sell | 221,014 | $10.96 | $2,422,313.44 | |
| 9/26/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,372,915 | $11.17 | $26,505,460.55 | |
| 9/25/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 497,986 | $11.05 | $5,502,745.30 | |
| 9/24/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 1,204,929 | $11.27 | $13,579,549.83 | |
| 9/23/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,595,071 | $11.29 | $29,298,351.59 | |
| 9/2/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 835,293 | $11.63 | $9,714,457.59 | |
| 8/27/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,711,352 | $11.33 | $30,719,618.16 | |
| 8/26/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 2,112,867 | $11.35 | $23,981,040.45 | |
| 8/25/2014 | Joseph Truitt | EVP | Sell | 25,000 | $10.82 | $270,500.00 | |
| 8/25/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 331,396 | $10.96 | $3,632,100.16 | |
| 8/18/2014 | Milind Deshpande | CEO | Sell | 216,624 | $10.00 | $2,166,240.00 | |
| 8/18/2014 | Ra Capital Management, Llc | Major Shareholder | Sell | 4,235,000 | $9.53 | $40,359,550.00 | |
| 8/15/2014 | Michael D Kishbauch | Director | Sell | 495,812 | $9.40 | $4,660,632.80 | |
| 8/13/2014 | Gary E Frashier | Director | Sell | 5,000 | $8.00 | $40,000.00 | |
| 6/20/2014 | Ra Capital Management, Llc | Insider | Sell | 880,000 | $8.40 | $7,392,000.00 | |
| 6/16/2014 | Gary E Frashier | Director | Sell | 55,000 | $8.00 | $440,000.00 | |
| 6/16/2014 | Joseph Truitt | EVP | Sell | 25,000 | $7.82 | $195,500.00 | |
| 6/16/2014 | Qvt Associates Gp Llc | Major Shareholder | Sell | 1,819,551 | $7.70 | $14,010,542.70 | |
| 6/11/2014 | Qvt Associates Gp Llc | Major Shareholder | Sell | 128,649 | $7.66 | $985,451.34 | |
| 6/10/2014 | Joseph Truitt | EVP | Sell | 50,000 | $6.02 | $301,000.00 | |
| 6/10/2014 | Michael D Kishbauch | Director | Sell | 371,937 | $7.75 | $2,882,511.75 | |
| 12/30/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 170,239 | $3.34 | $568,598.26 | |
| 12/26/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 121,205 | $3.44 | $416,945.20 | |
| 12/23/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 289,141 | $3.24 | $936,816.84 | |
| 12/19/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 222,612 | $3.09 | $687,871.08 | |
| 12/17/2013 | Qvt Associates Gp Llc | major shareholder | Sell | 92,803 | $3.11 | $288,617.33 | |
| 11/22/2013 | Dennis Liotta | Director | Buy | 10,000 | $2.98 | $29,800.00 | |
| 11/20/2013 | Ra Capital Management, Llc | Insider | Buy | 1,110,000 | $2.55 | $2,830,500.00 | |
| 11/19/2013 | Jason Fisherman | Director | Buy | 15,000 | $2.63 | $39,450.00 | |
| 11/12/2013 | Ra Capital Management, Llc | Insider | Buy | 1,795,000 | $2.48 | $4,451,600.00 | |
| 10/31/2013 | Ra Capital Management, Llc | Insider | Buy | 1,186,007 | $2.45 | $2,905,717.15 | |
| 10/14/2013 | Ra Capital Management, Llc | Insider | Buy | 2,369,229 | $2.79 | $6,610,148.91 | |
| 10/11/2013 | Ra Capital Management, Llc | Insider | Buy | 2,448,710 | $2.56 | $6,268,697.60 | |
| 9/30/2013 | Ra Capital Management, Llc | Insider | Buy | 2,800,000 | $2.98 | $8,344,000.00 | |
| 8/14/2013 | Jason Fisherman | Director | Buy | 5,000 | $6.83 | $34,150.00 | |
| 8/12/2013 | Dennis Liotta | Director | Buy | 5,000 | $6.47 | $32,350.00 | |
| 8/9/2013 | Qvt Associates Gp Llc | major shareholder | Buy | 102,282 | $6.41 | $655,627.62 | |
| 7/11/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 401,017 | $6.46 | $2,590,569.82 | |
| 7/10/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 390,944 | $6.33 | $2,474,675.52 | |
| 7/8/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 642,509 | $6.28 | $4,034,956.52 | |
| 7/3/2013 | Qvt Associates Gp Llc | Major Shareholder | Buy | 1,963,248 | $6.43 | $12,623,684.64 | |
| 7/1/2013 | Gary E Frashier | Director | Sell | 5,000 | $8.17 | $40,850.00 | |
| 6/21/2013 | Jason S Fisherman | Director | Buy | 10,000 | $7.63 | $76,300.00 | |
| 6/7/2013 | Gary E Frashier | Director | Sell | 5,000 | $8.37 | $41,850.00 | |
| 6/3/2013 | Jason S Fisherman | Director | Buy | 10,000 | $7.87 | $78,700.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Achillion Pharmaceuticals (NASDAQ:ACHN)
Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
| Source: |
|
| Date | Headline |
|---|
 | Achillion Pharmaceuticals, Inc. (ACHN) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - August 20 at 9:28 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 11 at 5:06 PM |
 | Corporate News Blog - Achillion Announces Proof-of-Concept with a First-in-Class, Oral Factor D Inhibitor
finance.yahoo.com - August 11 at 3:49 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 11 at 2:14 PM |
| Leerink Swann Comments on Achillion Pharmaceuticals, Inc.'s FY2017 Earnings (ACHN)
www.americanbankingnews.com - August 11 at 12:04 PM |
| William Blair Research Analysts Cut Earnings Estimates for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
www.americanbankingnews.com - August 11 at 12:04 PM |
| Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and ACADIA Pharmaceuticals
finance.yahoo.com - August 10 at 4:51 PM |
| Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : August 10, 2017
finance.yahoo.com - August 10 at 4:51 PM |
| Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence
finance.yahoo.com - August 10 at 4:51 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Stock Rating Lowered by Robert W. Baird
www.americanbankingnews.com - August 10 at 2:16 PM |
 | Health Care Sector Update for 08/09/2017: ACHN,NTRA,SGRY - Nasdaq
www.nasdaq.com - August 10 at 1:48 AM |
| Edited Transcript of ACHN earnings conference call or presentation 8-Aug-17 8:05pm GMT
finance.yahoo.com - August 9 at 8:46 PM |
| Achillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
finance.yahoo.com - August 9 at 8:46 PM |
| 3 Biotech Stocks Under the Microscope on Wednesday 8/9/17
finance.yahoo.com - August 9 at 8:46 PM |
| Maxim Group Analysts Give Achillion Pharmaceuticals, Inc. (ACHN) a $7.00 Price Target
www.americanbankingnews.com - August 9 at 6:46 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Releases Earnings Results, Meets Expectations
www.americanbankingnews.com - August 9 at 4:08 PM |
| BUZZ-US STOCKS ON THE MOVE-Priceline, Hertz, Natera, Surgical Partners - Nasdaq
www.nasdaq.com - August 9 at 3:44 PM |
| 2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
finance.yahoo.com - August 9 at 3:44 PM |
 | Why Achillion Pharmaceuticals Is Shooting 25% Higher Today
www.fool.com - August 9 at 2:04 PM |
| 2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
www.fool.com - August 9 at 2:04 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Price Target Cut to $4.00
www.americanbankingnews.com - August 9 at 9:00 AM |
 | Achillion shares rally as blood disorder treatment shows promise - MarketWatch
www.marketwatch.com - August 9 at 1:33 AM |
 | Achillion Pharmaceuticals' (ACHN) CEO Milind Deshpande on Q2 ... - Seeking Alpha
seekingalpha.com - August 9 at 1:33 AM |
| Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
finance.yahoo.com - August 8 at 8:27 PM |
| Achillion shares rally as blood disorder treatment shows promise
finance.yahoo.com - August 8 at 8:27 PM |
| Achillion reports 2Q loss
finance.yahoo.com - August 8 at 8:27 PM |
| Investor Network: Achillion Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 3:26 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - August 5 at 11:58 PM |
| Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017
finance.yahoo.com - August 1 at 8:38 PM |
| Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : August 1, 2017
finance.yahoo.com - August 1 at 8:38 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:10 AM |
| Analysts Anticipate Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to Post -$0.16 EPS
www.americanbankingnews.com - July 24 at 10:19 PM |
| Is the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock? - Nasdaq
www.nasdaq.com - July 20 at 3:27 PM |
| Is the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock?
finance.yahoo.com - July 20 at 3:27 PM |
| Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : July 19, 2017
finance.yahoo.com - July 19 at 3:33 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 18 at 8:32 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 10:49 AM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 10:14 PM |
 | Achillion Pharma (ACHN) Mingjun Huang Promoted to SVP & Head ... - StreetInsider.com
www.streetinsider.com - July 10 at 8:34 PM |
| Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - July 8 at 2:21 PM |
| Biotechs head higher ahead of Q2 earnings dump - Seeking Alpha
seekingalpha.com - July 5 at 3:33 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - June 28 at 6:26 PM |
| Achillion Pharmaceuticals Financials, Price Targets and Pipeline Review
finance.yahoo.com - June 22 at 1:05 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 20 at 8:34 AM |
 | Achillion to Present at the 2017 JMP Securities Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 16 at 3:31 PM |
| Achillion to Present at the 2017 JMP Securities Life Sciences Conference
finance.yahoo.com - June 15 at 8:27 PM |
| Achillion (ACHN) Up 31.1% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 9 at 3:21 PM |
| Achillion to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 6:18 PM |
| Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics
finance.yahoo.com - June 5 at 1:16 PM |
| Achillion Pharmaceuticals, Inc. (ACHN) Short Interest Update
www.americanbankingnews.com - May 27 at 7:06 AM |
Achillion Pharmaceuticals (ACHN) Chart for Sunday, August, 20, 2017
